TSC2 and tuberous sclerosis: If increased HDAC function in the TSC2+/− mouse model is primarily working to reduce global histone acetylation levels and repress target gene expression, identifying which transcription factor(s) are preferentially recruiting HDACs and then exploring the genes that may be differentially regulated with enhanced HDAC activity can help with developing therapeutic targets for TSC patients.